Abstract To evaluate the anti-diabetic effect of Fritillaria cirrhosa gold nanoparticles on Streptozotocin (STZ) stimulated diabetic preclinical models. The albino rats of either sex were equally distributed to five different groups. Group-I represented as Control; Group-II represented as diabetic control (STZ alone); Group-III represented as 10 mg/kg body weight of Fritillaria cirrhosa gold nanoparticles + diabetes; Group-IV represented as 20 mg/kg body weight of Fritillaria cirrhosa gold nanoparticles + diabetes; Group-V represented as 0.1 mg/kg body weight of glibenclamide + diabetes. The animals were killed after the experimental period. The blood and organs samples were gathered and stored for the additional investigations. The gold nanoparticles were inspected via the UV spectrophotometer, HR-TEM, XRD and FT-IR techniques. The bodyweight, kidney and liver weight were tabulated. The food and water consumption were monitored in all the experimental rats. The serum markers, hepatic markers and renal markers were quantified in both normal and investigational rats. The lipid peroxidation and antioxidant status were quantified in the control and experimental rats. The histopathological alterations were also studied in all the experimental animals. The standard drug glibenclamide was used to compare the synthesized AuNPs. The study revealed that the AuNPs treatment restores the serum, hepatic and renal marker in the STZ-challenged diabetic rats. The AuNPs treatment modulates the antioxidants level and decreased the lipid peroxidation by its antioxidant properties. The pathology results revealed that the AuNPs treatment induces the regeneration of islets cells of pancreas in the experimental rats. The research study proved that the Fritillaria cirrhosa AuNPs exerts anti-diabetic properties.

中文翻译：

---

肝贝母金纳米粒子的绿色合成及其对链脲佐菌素诱导大鼠的抗糖尿病活性

摘要 评价肝贝母金纳米粒对链脲佐菌素（STZ）刺激的糖尿病临床前模型的抗糖尿病作用。两种性别的白化大鼠均等地分配到五个不同的组中。Group-I 表示为 Control；第 II 组代表糖尿病对照（单独的 STZ）；第III组表示为10mg/kg体重的肝贝母金纳米粒子+糖尿病；第IV组表示为20mg/kg体重的肝贝母金纳米粒子+糖尿病；V组表示为0.1mg/kg体重的格列本脲+糖尿病。实验期结束后处死动物。收集并储存血液和器官样本以供进一步调查。通过紫外分光光度计、HR-TEM、XRD 和 FT-IR 技术检测金纳米粒子。体重，肾脏和肝脏的重量被制成表格。在所有实验大鼠中监测食物和水的消耗。在正常和研究大鼠中量化血清标志物、肝脏标志物和肾脏标志物。在对照和实验大鼠中量化脂质过氧化和抗氧化状态。还在所有实验动物中研究了组织病理学改变。标准药物格列本脲用于比较合成的 AuNP。研究表明，AuNPs 治疗可恢复 STZ 攻击的糖尿病大鼠的血清、肝脏和肾脏标志物。AuNPs处理调节抗氧化剂水平并通过其抗氧化特性降低脂质过氧化。病理结果表明，AuNPs 处理诱导实验大鼠胰腺胰岛细胞的再生。研究证明，肝贝母 AuNPs 具有抗糖尿病特性。